MASLD or MAFLD: fatty liver by any name will pose the same challenge

Anil Chandra Anand , Dibyalochan Praharaj

Metabolism and Target Organ Damage ›› 2025, Vol. 5 ›› Issue (2) : 20

PDF
Metabolism and Target Organ Damage ›› 2025, Vol. 5 ›› Issue (2) :20 DOI: 10.20517/mtod.2025.18
review-article

MASLD or MAFLD: fatty liver by any name will pose the same challenge

Author information +
History +
PDF

Cite this article

Download citation ▾
Anil Chandra Anand, Dibyalochan Praharaj. MASLD or MAFLD: fatty liver by any name will pose the same challenge. Metabolism and Target Organ Damage, 2025, 5(2): 20 DOI:10.20517/mtod.2025.18

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

LonardoA,AlswatKA.History of nonalcoholic fatty liver disease.Int J Mol Sci2020;21:5888 PMCID:PMC7460697

[2]

LudwigJ,McGillDB.Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.Mayo Clin Proc1980;55:434-8

[3]

SchaffnerF.Nonalcoholic fatty liver disease.Prog Liver Dis1986;8:283-98

[4]

YounossiZM,PaikJM,Van DongenC.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023;77:1335-47 PMCID:PMC10026948

[5]

BattistellaS,GrassoM.Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management.Clin Mol Hepatol2023;29:S286-301 PMCID:PMC10029965

[6]

DaherD,SingalAG.Non-alcoholic fatty liver disease-related hepatocellular carcinoma.J Liver Cancer2023;23:127-42 PMCID:PMC10202236

[7]

GranderC,TilgH.Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options.Cardiovasc Res2023;119:1787-98 PMCID:PMC10405569

[8]

Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1.

[9]

Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86. PMCID:PMC10653297

[10]

Lancet Gastroenterology Hepatology. Redefining non-alcoholic fatty liver disease: what’s in a name?.Lancet Gastroenterol Hepatol2020;5:419

[11]

PremkumarM.Lean fatty liver disease: through thick and thin.J Clin Exp Hepatol2021;11:523-7 PMCID:PMC8414406

[12]

ChenL.From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: controversy and consensus.World J Hepatol2023;15:1253-7 PMCID:PMC10784812

[13]

FouadY.Metabolic-associated fatty liver disease: new nomenclature and approach with hot debate.World J Hepatol2023;15:123-8 PMCID:PMC10011913

[14]

DusejaA,MehtaM.Patients with metabolic-dysfunction associated fatty liver disease (MAFLD) without associated etiologies and non-MAFLD non-alcoholic fatty liver disease (NAFLD) have similar liver disease severity - data from Indian Consortium on NAFLD (ICON-D).J Clin Exp Hepatol2022;12:S73-4

[15]

GoftonC,ZhengMH.MAFLD: how is it different from NAFLD?.Clin Mol Hepatol2023;29:S17-31 PMCID:PMC10029949

[16]

AlbhaisiS,SanyalAJ.Non-alcoholic fatty liver disease in lean individuals.JHEP Rep2019;1:329-41 PMCID:PMC7001558

[17]

SinghSP,ReddyKR.Non-alcoholic fatty liver disease: not time for an obituary just yet!.J Hepatol2021;74:972-4

[18]

DusejaA.Changing nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease - not only premature but also confusing.J Clin Exp Hepatol2021;11:278-9 PMCID:PMC7953006

[19]

SinghSP,ButtAS.NAFLD vs MAFLD: South Asian NAFLD patients don’t favor name change.Euroasian J Hepatogastroenterol2022;12:S1-4 PMCID:PMC9681577

[20]

YounossiZM,SanyalAJ.From NAFLD to MAFLD: implications of a premature change in terminology.Hepatology2021;73:1194-8

[21]

Society for Paediatric Gastroenterology Hepatology (ESPGHAN) and European Association for the Study of the Liver (EASL), on behalf of co-authors. Electronic address: j.p.mann@bham.ac.uk; European Society for Paediatric Gastroenterology Hepatology (ESPGHAN) and European Association for the Study of the Liver (EASL), on behalf of co-authors. Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease.Lancet Gastroenterol Hepatol2023;8:598-600

[22]

SinghSP,AnirvanP,MahtabMA.Nonalcoholic fatty liver disease vs metabolic-associated fatty liver disease vs metabolic dysfunction-associated steatotic liver disease: what’s in the name?.Euroasian J Hepatogastroenterol2024;14:1-4 PMCID:PMC11249896

[23]

García-Compeán D, Jiménez-Rodríguez AR. NAFLD vs MAFLD. The evidence-based debate has come. Time to change? Ann Hepatol. 2022;27:100765.

[24]

AnandAC.MASLD, MLA pesarattu and other developments.J Clin Exp Hepatol2025;15:102465 PMCID:PMC11663955

[25]

SchuckitMA,SmithTL.Characteristics associated with denial of problem drinking among two generations of individuals with alcohol use disorders.Drug Alcohol Depend2020;217:108274 PMCID:PMC7736262

[26]

PortincasaP.NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care.Intern Emerg Med2023;18:993-1006 PMCID:PMC10326150

[27]

ArabJP,RehmJ.Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease.J Hepatol2025;82:744-56

[28]

Israelsen M, Torp N, Johansen S, et al; GALAXY consortium. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024;9:218-28.

AI Summary AI Mindmap
PDF

80

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/